Top

News & Events

Client News

Client News

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform

Ingelheim am Rhein, Germany and Geneva, Switzerland – Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunization platform.

Read more »

Imugene Enhances Portfolio with Compelling Oncolytic Virus from City of Hope, a Cancer Centre in Los Angeles, California

SYDNEY Australia – Australian immuno-oncology company Imugene Ltd (ASX:IMU), today announced it would acquire Vaxinia Pty Ltd and separately acquire a worldwide exclusive license to a promising oncolytic virus technology, known as CF33, developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in Los Angeles, California.

Read more »

HOOKIPA Announces FDA Clearance of IND Application for HB-201 Clinical Trial to Treat HPV-Positive Cancers

New York, US and Vienna, Austria - HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that its Investigational New Drug (IND) Application for a Phase 1/2 clinical trial of HB-201, a TheraT®*-based immunotherapy, for the treatment of Human Papilloma Virus (HPV)-positive cancers is now effective following the clearance by the U.S. Food and Drug Administration (FDA).

Read more »

Prescient Therapeutics Initiates Phase 1b Clinical Trial for First-in Class Anti-Cancer Drug PTX-100 in Patients with Multiple Cancers

MELBOURNE Australia – Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, today announced the start of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in Australia.

Read more »

Dr Neil Thompson Appointed Chief Scientific Officer of Healx to Spearhead Drug Discovery Expansion

Cambridge, UK – Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announces the appointment of Dr Neil Thompson, PhD, as Chief Scientific Officer (CSO).

Read more »

Outcome of strategic review and trading update

Cambridge, UK - Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces the outcome of its strategic review following the appointment of Dr Tom Oakley as CEO in April 2019. The Board is also pleased to provide a trading update on the year ended 31 May 2019.

Read more »

Recce Board Changes - Appointment of Independent Chair and Additional Director

SYDNEY, Australia - Recce Pharmaceuticals Ltd (ASX: RCE, “Recce” or the “Company”), the company developing a new class of synthetic antibiotics, today announced that Dr John Prendergast has been appointed to Independent Chair with founder Dr Graham Melrose stepping back from the role of Executive Chair to Executive Director and Chief Research Officer. In addition, the Company’s Principle Chemist, Dr Justin Ward, has been appointed to the Board as Executive Director. These changes are effective today.

Read more »

Imugene: New HER-Vaxx Cancer Vaccine trial data presented at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer

SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced new clinical data from the Phase Ib study of its HER-Vaxx cancer vaccine showing cancer fighting antibody and clinical response rates continue to be positive in the patients receiving the optimal biological dose of vaccine.

Read more »

Immatics Appoints Harpreet Singh as Chief Executive Officer

Tuebingen, Germany and Houston, Texas – Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer (CEO).

Read more »

Seventure Partners Announces First Close of New Fund, Sport & Performance Capital

Paris, France Seventure Partners, one of Europe’s leaders in financing innovation in Life sciences and associated industries, announces the launch of Sport & Performance Capital™, a new fund dedicated to supporting innovation in the sport and wellness industries. With a final target of €80 million, the venture fund will invest in startup companies and growing SMEs furthering physical activity to help promote health and physical fitness.

Read more »

Business Update and Board Changes

Manchester, UK – 4 July 2019 - SkinBioTherapeutics plc (AIM: SBTX or the “Company”), a life sciences company focused on skin health, announces changes to its Board and executive team and provides a business update.

Read more »

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

Ghent, Belgium, and Dresden, Germany - Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR).

Read more »

Seventure Partners Life Sciences Corporate Update Health for Life: March 2019 – June 2019

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, is pleased to provide an update on its Health for Life investments for the period March 2019 to June 2019 (Note: June 27 is now marked The World Microbiome Day).

Read more »

RevoluGen announces a global distribution agreement for its combined High Molecular Weight DNA (HMW-DNA) extraction and size selection product Fire Monkey / Fire Flower with Merck

Hadfield, UK – RevoluGen Limited announced today a global distribution agreement for its Fire Monkey / Fire Flower product with Merck. The Fire Monkey / Fire Flower product is a kit that can be used to perform either the Fire Monkey purification of DNA for long-read sequencing applications, utilizing its reliable, rapid, user friendly protocol, or to perform the Fire Flower DNA size selection protocol.

Read more »

Emergex Signs an R&D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot & Mouth Disease

Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.

Read more »

RevoluGen Appoints Stefano Giolito as Chief Marketing Officer

Ascot, UK – RevoluGen, a privately held scientific company specialising in the development and commercialisation of nucleic acid isolation and purification products, today announces the appointment of Stefano Giolito as Chief Marketing Officer, effective immediately.

Read more »

Clinigen - MHRA licenses two Melatonin products indicated for short-term jet-lag treatment in adults

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has been granted marketing authorisations for Melatonin 1mg/ml Oral Solution and Melatonin 3mg Film-Coated Tablets by the Medicines and Healthcare products Regulatory Agency (MHRA). Both forms are indicated for the short-term treatment of jet-lag in adults.

Read more »

Clinigen broadens partnership with Accord Healthcare to supply and distribute Cardioxane® and Savene® in Poland

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Commercial Medicines business has signed an exclusive agreement with Accord Healthcare (‘Accord’) to supply and distribute Clinigen’s speciality medicines, Cardioxane® and Savene® in Poland.

Read more »

Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication

Ghent, Belgium – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the Company’s proprietary pre-clinical programs, targeting a neurological orphan indication.

Read more »

Microbiotica Presenting at Key Industry Events during Summer 2019

Cambridge, UK - Microbiotica, a leading player in microbiome-based therapeutics, is pleased to confirm upcoming conference attendance and during summer 2019. CEO Dr Mike Romanos, CSO Dr Trevor Lawley and Head of Bioinformatics Dr Simon Harris will be presenting on commercial and scientific advances and opportunities in the fast-moving microbiome space.

Read more »

British Company Behind Groundbreaking Breast Cancer Treatment

Cambridge, UK - A new set of statistically significant overall survival (OS) data unveiled at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract# LBA1008), and published in The New England Journal of Medicine, are being heralded as a major breakthrough for pre- and perimenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer premenopausal women with advanced breast cancer.

Read more »

Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASCERTAIN study of the novel oral cedazuridine and decitabine fixed-dose combination (ASTX727) in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML)

Pleasanton, CA and Tokyo, Japan - Astex Pharmaceuticals, Inc. a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co. Ltd., announce top-line results from the ASCERTAIN phase 3 study evaluating cedazuridine and decitabine fixed-dose combination (ASTX727) vs decitabine IV in adults with intermediate and high-risk MDS or CMML.

Read more »

Updated Phase Ib HER-Vaxx data presented at the American Society of Clinical Oncology 2019 Annual Meeting

SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cancer vaccine was presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting in Chicago Illinois, USA 31 May to 3 June 2019.

Read more »

National Care Group expands into Wales for the first time with the acquisition of the Integra Group

Accrington, UK – National Care Group (“NCG”), a leading provider of support services, announces the acquisition of the business and assets of the Integra Group (“Integra”). Financial details of the deal were not disclosed.

Read more »

Leading Physician to Chair Clinical Advisory Committee

SYDNEY, Australia – Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the company developing a new class of synthetic antibiotics, today announced the formation of a Clinical Advisory Committee to assist in the Board’s growing clinical considerations under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS).

Read more »